Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

Sanofi exercises license extension option to Nurix’s STAT6 program

his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days

Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business

Biocon gets approval for diabetes drug Liraglutide in India

The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus

Fluor-built Bayer cell therapy facility in California achieves LEED v4 platinum certification

Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs

Sun Pharma to raise stake in US-based Pharmazz to 22.7%

Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%

Shilpa Medicare partners with Orion for Recombinant Human Albumin for European market

Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion

Emcutix launches urea-based skin-care moisturizers ‘Ureaderm'

Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.